HCV Protease

Sofosbuvir impurity A, an diastereoisomer of sofosbuvir, is the impurity of sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.

NM107 (2'-C-Methylcytidine) is an nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase, the EC50 of NM107 in the wild-type replicon cells is 1.85 μM.

PSI-6206 13CD3 is the deuterium labeled PSI-6206. PSI-6206 is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase.

HZ-1157 is an inhibitor of hepatitis C virus (HCV) with inhibitory activities toward HCV NS3/4A protease.

JTK-853 is a novel, non-nucleoside Hepatitis C Virus (HCV) polymerase inhibitor which shows effective antiviral activity in HCV replicon cells with EC50s of 0.38 and 0.035 ?M in genotype 1a H77 and 1b Con1 strains, respectively.

ACH-806 is an NS4A antagonist which can inhibit Hepatitis C Virus (HCV) replication with an EC50 of 14 nM.

HCV-IN-3 is a hepatitis C virus (HCV) NS3/4a protein inhibitor, with an IC50 of 20 μM, a Kd of 29 μM.

PSI-352938 (PSI-938) is a hepatitis C virus (HCV) nucleotide inhibitor.

Beclabuvir is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, and inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 with IC50 of < 28 nM.

ABT-072 is a nonnucleoside NS5B polymerase inhibitor and a candidate drug evaluated for treatment of hepatitis C virus.

MK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development.

MK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development.

MK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development.

RO-9187 is a potent inhibitor of HCV virus replication in the replicon system (IC(50) = 171 +/- 12 nM; CC(50) >1 mM).

Roseoside is a potent inhibitor targeting the HCV NS5A/B replicase, demonstrating an IC50 of 20 μM. This compound effectively interferes with HCV RNA replication in vitro and exhibits antibacterial properties against both Gram-positive and Gram-negative bacteria, as well as antifungal activity against Candida albicans. Roseoside serves as a valuable research tool for investigating bacterial infections, candidiasis, and Hepatitis A and C virus mechanisms, while demonstrating no cytotoxic effects in human systems.